This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HDAC9 / Histone deacetylase 9 · IHC design guide
Design Immunohistochemistry for HDAC9
Plan chromogenic HDAC9 IHC on paraffin sections with a mainly nuclear readout (HPA tissue IHC). Use high-staining glandular or hematopoietic cells as positive references, and interpret staining cautiously because tissue-IHC reliability is uncertain (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HDAC9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Mainly nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in glandular and hematopoietic cells (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Hippocampus+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining has uncertain reliability (HPA tissue IHC) | |
| Regulation | No expression trigger is specified (UniProt) | |
| Isoform / epitope | 11 isoforms; splice-dependent epitope coverage is possible (UniProt) |
Section 1
Recommended HDAC9 IHC & IF Protocols
The catalog antibody has an IHC-P protocol; the published protocol below describes chromogenic HDAC9 staining of paraffin sections in arteries (PMC4206941).
| Sample | Paraffin-embedded human brain tissue; fixative not specified (datasheet M02177) |
| Fixation | Image fixative and duration unreported (datasheet M02177); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit monoclonal (clone HEF-8) anti-HDAC9, 1:50-1:200 (datasheet M02177) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HDAC9-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Mainly general nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the published artery protocol uses a different retrieval condition (PMC4206941).
Section 2
What Is the Expected HDAC9 Staining Pattern?
HDAC9 is a nuclear protein with no transmembrane segment (UniProt Q9UKV0: location and topology). In paraffin sections, expect mainly nuclear staining across multiple cell types, including glandular, respiratory epithelial and hematopoietic cells (HPA: mainly general nuclear expression; High in the listed cells). Interpret intensity by cell type and tissue: HPA rates tissue IHC reliability as Uncertain because staining and RNA show medium consistency and external verification is pending (HPA: reliability).
| Distinct nuclear staining in adrenal, breast, cervical, colonic, duodenal or endometrial glandular cells. | This fits the reported High staining in those glandular cells (HPA: tissue IHC). Score nuclei within the specified cell population; a positive region does not make every cell in the section positive. HPA's Uncertain reliability calls for a cautious interpretation (HPA: reliability). |
| Nuclear staining in bronchial respiratory epithelial cells or bone marrow hematopoietic cells. | Both are reported High and provide additional expected patterns to compare with the test section (HPA: tissue IHC). The expected compartment is nuclear (HPA: tissue IHC profile; UniProt Q9UKV0: location). Check that apparent staining is associated with nuclei rather than a layer of surface deposit. |
| Predominantly cytoplasmic, membranous or extracellular color, with little nuclear staining. | That distribution conflicts with the mainly nuclear IHC profile and nuclear protein location (HPA: tissue IHC profile; UniProt Q9UKV0: location and topology). Treat it as suspect until controls clarify whether it reflects background, detection chemistry or antibody binding. The supplied sources do not validate a tissue IHC pattern in those compartments. |
| Strong color in a cell type reported as Not detected, such as hippocampal glia or parathyroid glandular cells. | This conflicts with the named HPA observations (HPA: Not detected in hippocampal glia and parathyroid glandular cells). Consider cross-reactivity or endogenous detection activity, especially if nuclear staining is absent from a reported High cell population. A mismatch alone cannot identify which mechanism caused the signal (HPA: IHC reliability Uncertain). |
| Diffuse color across nuclei and surrounding tissue, or no signal in a reported High cell population. | Diffuse color obscures compartment scoring; absent color in a reported High population prevents confirmation against that HPA pattern (HPA: tissue IHC). These results are inconclusive until general IHC controls and detection conditions are checked. HPA's High category is an observed pattern, not a guarantee for every specimen (HPA: reliability Uncertain). |
💡Expected HDAC9 appearanceCall a positive result when clearly resolved nuclei show strong staining in an HPA High cell population, such as bronchial respiratory epithelium or bone marrow hematopoietic cells (HPA: tissue IHC); diffuse color outside nuclei is suspect against the mainly nuclear profile (HPA: tissue IHC profile).
| Tissue and cell selection | HPA reports High staining in several glandular populations, bronchial respiratory epithelium and bone marrow hematopoietic cells, but Not detected in hippocampal glia and parathyroid glandular cells (HPA: tissue IHC). Compare like cell types when choosing a reference region; whole-tissue labels can hide differences between populations. |
| IHC evidence strength | The tissue IHC profile is mainly general nuclear expression, but its reliability is Uncertain; antibody HPA028926 is also rated IHC Uncertain (HPA: tissue IHC reliability; HPA: antibody validation). Use the reported pattern as a provisional benchmark and give discrepancies more scrutiny than a fully verified profile would require. |
| Tissue expression is not uniform | UniProt describes broad expression with highest levels in brain, heart, muscle and testis (UniProt Q9UKV0: tissue specificity). HPA instead reports Low staining in cardiomyocytes and caudate glia and Not detected in hippocampal glia (HPA: tissue IHC). Use the specified IHC cell population to interpret a slide, rather than inferring staining intensity from a broad expression statement. |
| Isoforms and antibody coverage | UniProt lists 11 HDAC9 isoforms (UniProt Q9UKV0: isoforms). The supplied evidence gives no epitope or isoform coverage for the IHC antibody, so an unexpected result cannot be assigned to a particular isoform. Check the antibody's documented target region before making an isoform-specific interpretation. |
| Compartment and processing | UniProt places HDAC9 in the nucleus, reports no transmembrane segment, signal peptide or propeptide, and annotates a chain spanning residues 1–1011 (UniProt Q9UKV0: location, topology and processing). These annotations support nuclear scoring; they provide no basis for interpreting extracellular staining as normal shedding. |
| Situation | Likely cause | Next action |
|---|---|---|
| A reported High population shows no convincing nuclear signal. | The expected HPA observation is missing; the supplied sources do not establish a target-specific reason, and IHC reliability is Uncertain (HPA: tissue IHC). | As general IHC practice, verify tissue identity and detection controls, then review the documented retrieval and antibody conditions. Compare nuclei in a second reported High population if available (HPA: tissue IHC). |
| Color appears mainly outside nuclei. | The compartment differs from the mainly nuclear IHC profile and UniProt nuclear location (HPA: tissue IHC profile; UniProt Q9UKV0: location). | As general IHC practice, inspect a no-primary control for detection background and assess whether deposit follows tissue edges or damaged areas. Score HDAC9 only where nuclear signal is distinguishable. |
| Parathyroid glandular cells or hippocampal glia appear strongly positive. | Those populations are reported Not detected; cross-reactivity or endogenous detection activity is possible, though the source data cannot distinguish them (HPA: tissue IHC). | As general IHC practice, compare with a no-primary control and a reported High cell population. Record the discrepant cell type and compartment rather than calling the whole section uniformly positive. |
| Diffuse staining makes positive nuclei hard to distinguish. | Background can obscure the mainly nuclear pattern (HPA: tissue IHC profile); the supplied evidence does not identify a target-specific background mechanism. | As general IHC practice, check blocking, detection controls, washing and counterstain balance. Reassess whether individual nuclei can be scored after background is resolved. |
| Heart muscle looks weak despite UniProt's high-expression description. | The sources describe different observations: UniProt lists heart among highest-expression tissues, while HPA scores cardiomyocytes Low by IHC (UniProt Q9UKV0: tissue specificity; HPA: tissue IHC). | Interpret the cardiomyocyte slide against HPA's Low IHC observation, and use an HPA High cell population when a stronger tissue IHC reference is needed (HPA: tissue IHC). |
| IF/ICC question: where should HDAC9 appear? | HPA approves nucleoplasm as the main ICC-IF location and mitotic chromosomes as an additional location; HPA028926 has ICC Approved status (HPA: subcellular; HPA: antibody validation). | For IF/ICC interpretation, look for nucleoplasmic signal and recognize mitotic chromosome staining as an additional reported pattern (HPA: subcellular). Use the separate IF/ICC guide for that application. |
Experiment evidence
IHC & IF images showing HDAC9 staining
M02177 · IHCImmunohistochemical analysis of paraffin-embedded human brain, using HDAC9 Antibody.
M02177 · IFImmunofluorescent analysis of Hela cells, using HDAC9 Antibody.
A02177-4 · IFIF analysis of HDAC9 using anti-HDAC9 antibody (A02177-4). HDAC9 was detected in immunocytochemical section of Hela cells. Enzyme antigen re
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000048052-HDAC9/tissue/cerebral+cortex#imid_7884344
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000048052-HDAC9/tissue/colon#imid_7878574
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000048052-HDAC9/tissue/liver#imid_7878575
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000048052-HDAC9/tissue/kidney#imid_7878584
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028926; green = HDAC9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028926; green = HDAC9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HDAC9 IHC & IF
🧪Run breast first and look for HDAC9 staining in glandular cells (HPA: High in breast glandular cells); use parathyroid glandular cells as the negative tissue comparator (HPA: Not detected in parathyroid glandular cells). On the breast slide, adjacent non-glandular cells should show no specific nuclear chromogen to qualify as internal negatives, but their HDAC9 status must be checked rather than assumed (UniProt Q9UKV0: Nucleus; HPA: High in breast glandular cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Hippocampus (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HDAC9 in A-431, U-251MG, U2OS, KOLF2.1J, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-species- and immunoglobulin-class-matched isotype controls, plus HDAC9 knockout tissue or an immunizing-peptide competition control when available (standard IHC practice). Block endogenous peroxidase on the breast section before chromogenic detection and assess residual background against those controls (standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence; the fixative for the selected M02177 paraffin-section caption is unreported (selected-SKU tissue-IHC caption). Antigen-retrieval dependency is unreported, so optimize retrieval on the positive section before interpreting a negative result (standard IHC practice; HPA: High in breast glandular cells). The supplied evidence does not establish whether frozen sections or IF are easier, and reports no breast-specific artefact.
HPA tissue IHC evidence for HDAC9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
Section 3
Advanced HDAC9 IHC Tips
Troubleshoot HDAC9 staining in paraffin sections by checking nuclear localisation, cell-level controls, and assay conditions before interpreting chromogenic signal (UniProt: nucleus; HPA: mainly general nuclear expression).
How should I retrieve HDAC9 in paraffin sections when nuclear staining is weak?
Use Tris-EDTA at pH 9.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting: nuclear antigen). Let sections cool in retrieval buffer, then compare staining with a concurrently processed positive control and a no-primary control (standard IHC practice). If nuclear signal remains weak, test a citrate buffer at pH 6.0 on adjacent sections as a fallback, keeping detection conditions constant (standard IHC optimisation). Judge any gain by nuclear staining with preserved morphology, since HDAC9 is annotated as nuclear and the tissue profile is mainly nuclear (UniProt: nucleus; HPA: mainly general nuclear expression).
Could fixation explain weak or patchy HDAC9 staining?
Target-specific fixation sensitivity is unknown from the supplied evidence; the catalog image identifies paraffin-embedded human brain but does not state its fixative (M02177 caption). Record the actual fixative and fixation duration for each specimen before comparing staining across blocks (standard IHC practice). On matched sections, keep retrieval at Tris-EDTA pH 9.0, 95–98 °C for 20 min while checking whether nuclear signal and morphology vary between blocks (page retrieval setting; standard IHC practice). Use a no-primary control to identify detection background, and avoid assigning a block-to-block difference to HDAC9 biology until processing differences have been assessed (standard IHC practice).
What should I check if HDAC9 staining looks predominantly cytoplasmic?
Start by scoring nuclear and cytoplasmic signal separately: HDAC9 is annotated as nuclear, and tissue staining is described as mainly general nuclear expression (UniProt: nucleus; HPA: tissue profile). Nucleoplasmic localisation is also supported by cell imaging, with additional signal on mitotic chromosomes (HPA: approved subcellular locations). Check whether the apparent cytoplasmic colour persists on a no-primary section or tracks folds and tissue edges (standard IHC practice). Review a nuclear counterstain at higher magnification so that pigment overlying crowded cells is not mistaken for nuclear signal (standard IHC practice). Treat predominant cytoplasmic staining as unresolved until controls support its specificity (standard IHC interpretation).
How do HDAC9 isoforms and phosphorylation affect interpretation of a negative stain?
HDAC9 has 11 listed isoforms, so an antibody may miss a variant if its recognised epitope is absent from that variant (UniProt: isoforms 1–11; standard epitope principle). The supplied evidence does not locate the catalog antibody’s epitope; check its documentation before claiming coverage of every isoform (supplied product evidence: epitope unspecified). HDAC9 also has annotated phosphoserines, including positions 22, 220, 240, 451 and 554, but their effect on this antibody is unknown (UniProt: modified residues; supplied product evidence: epitope unspecified). Pair a negative tissue result with a processed positive control and report it as undetected staining under the tested conditions (standard IHC practice).
How can I follow up chromogenic HDAC9 staining with multiplex IF?
Treat IF as a separate assay to optimise, using nuclear HDAC9 signal as the localisation benchmark (UniProt: nucleus; HPA: approved nucleoplasmic location). Multiplex with a validated marker for the expected cell population in the specimen, and verify each channel alone before interpreting overlap (standard IF practice). Choose a fluorophore channel with low measured tissue autofluorescence, and include unstained and secondary-only sections to assess background (standard IF practice). For this intracellular protein, optimise permeabilisation to admit antibody to the nuclear epitope while retaining nuclear morphology; HDAC9 has no annotated transmembrane segment (UniProt: topology; standard IF practice). Do not transfer a paraffin IHC condition directly into an IF claim (M02177 caption: paraffin IHC).
How do I reduce diffuse brown staining without losing nuclear HDAC9 signal?
First inspect a no-primary section for signal caused by the detection system and run a reagent blank when endogenous enzyme activity is suspected (standard chromogenic IHC practice). Block endogenous peroxidase for an HRP/DAB workflow, and use an appropriate protein block while keeping section handling consistent (standard chromogenic IHC practice). If background persists, titrate the primary antibody and shorten detection development on matched sections rather than changing several variables together (standard IHC optimisation). Compare the result with nuclear morphology and a positive control: expected HDAC9 staining is mainly nuclear, whereas diffuse extracellular colour does not fit that profile (UniProt: nucleus; HPA: mainly general nuclear expression).
How should I quantify heterogeneous HDAC9 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define cell populations and regions before scoring, then record the percentage of positive nuclei and nuclear intensity using the same threshold across specimens (standard IHC quantification). An H-score can combine percentages at intensity grades 0–3; retain the underlying percentages so a change in intensity is distinguishable from a change in positive-cell fraction (standard IHC quantification). Normalise positive nuclei to evaluable nuclei of the same cell population, or report positive-cell density per mm² of evaluable tissue when cell density matters (standard IHC quantification). Exclude damaged edges and necrotic areas by a prespecified rule, and interpret small differences cautiously because HPA rates tissue staining reliability as uncertain (standard IHC practice; HPA: uncertain reliability).
When is an HDAC9-positive result convincing rather than an artefact?
A convincing result shows signal associated with intact nuclei and reproduces in appropriately processed controls, matching HDAC9’s nuclear annotation and mainly nuclear tissue profile (UniProt: nucleus; HPA: tissue profile; standard IHC practice). Check the expected cell population explicitly: HPA reports high staining in adrenal glandular cells but no detected staining in hippocampal glial cells (HPA: tissue IHC). Colour confined to section edges, necrotic areas or a no-primary control warrants investigation before it is scored as positive (standard IHC practice). For HRP/DAB detection, assess endogenous peroxidase background with the relevant control, and qualify conclusions because the HPA tissue assessment remains uncertain pending external verification (standard chromogenic IHC practice; HPA: reliability).
Boster reagents
Best HDAC9 / Histone deacetylase 9 IHC Antibodies
HDAC9 antibodies have human brain paraffin-section IHC data (M02177 IHC image caption) and HeLa-cell IF data (A02177-4 IF image caption); catalog reactivity also covers rat and mouse (catalog reactivity lists).
Real IHC data
Anti-HDAC9 Rabbit Monoclonal Antibody
Cat # M02177
Real IF data
Anti-HDAC9 Antibody ®
Cat # A02177-4
M02177 will render with IHC data from paraffin-embedded human brain; its listed reactivity is human and rat (M02177 IHC image caption; catalog reactivity list). A02177-4 will render with IF data from HeLa cells; its listed reactivity is human, mouse and rat (A02177-4 IF image caption; catalog reactivity list).
Which to pick: Choose M02177 for paraffin-section IHC: it is a rabbit monoclonal with IHC listed at 1:50–1:200 and an IHC image from paraffin-embedded human brain; the fixative is unreported (M02177 catalog application and dilution lists; M02177 IHC image caption). Choose A02177-4 for IF/ICC using the documented 4 μg/mL HeLa-cell IF example; M02177 also lists ICC/IF, but its rendered card uses its IHC image (A02177-4 IF image caption; M02177 catalog application list). For mouse-reactive IF/ICC, A02177-4 lists mouse alongside human and rat, while M02177 lists human and rat; the supplied mouse reactivity is a catalog claim, not a mouse IHC figure (catalog reactivity and application lists; M02177 IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UKV0 (HDAC9_HUMAN, Histone deacetylase 9).
- Human Protein Atlas. HDAC9 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. HDAC9 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the mitotic chromosome..
- Human Protein Atlas. HDAC9 antibody validation summary (1 antibodies).
- Evidence HDAC9 genetic variant associated with ischemic stroke increases risk via promoting carotid atherosclerosis. Stroke 2013 — PMC4206941.
- Nucleocytoplasmic Shuttling of Histone Deacetylase 9 Controls Activity-Dependent Thalamocortical Axon Branching. Scientific reports 2017 — PMC5519695.
- Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PloS one 2022 — PMC8884513.
- HDAC9 deficiency promotes tumor progression by decreasing the CD8(+) dendritic cell infiltration of the tumor microenvironment. Journal for immunotherapy of cancer 2020 — PMC7304847.
- PubMed PMID:11535832 — UniProt-cited evidence.
- PubMed PMID:12706107 — UniProt-cited evidence.
- PubMed PMID:12590135 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HDAC9 (Histone deacetylase 9). Expected localisation Mainly nuclear tissue staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: M02177 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Hippocampus. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human brain tissue; fixative not specified (datasheet M02177); 2. Fixation: Image fixative and duration unreported (datasheet M02177); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit monoclonal (clone HEF-8) anti-HDAC9, 1:50-1:200 (datasheet M02177); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Tissue staining has uncertain reliability (HPA tissue IHC); Isoform / epitope: 11 isoforms; splice-dependent epitope coverage is possible (UniProt); Regulation: No expression trigger is specified (UniProt). Evidence: UniProt Q9UKV0, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M02177, PMC4206941. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HDAC9/immunohistochemistry-ihc-guide.